Fig. 7: Plasma levels of Tgfβ1 as a predictor of MO-/PMN-MDSC ratio among tumor patients.
From: Downregulated Smad3 signaling impairs the maturation of MO-MDSC in colorectal cancer
(A) FCM analysis of the correlations between Mettl3 and Smad3 in MO-MDSC derived from CRC patients (n = 28). (B) FCM analysis of the Smad3 expressions in CD33+CD14+CD15–HLA-DRlo MO-MDSC and CD33+CD14–CD15+HLA-DR–PMN-MDSC derived from CRC patients (n = 28). (C) ELISA assays analysis of the concentrations of circulatory Tgfβ1 in the peripheral blood of ovarian cancer (OC), CRC, and breast cancer (BC) patients. (D–F) Analysis the correlations of plasma Tgfβ1 concentration with MO-/PMN-MDSC ratio in the peripheral blood of CRC, ovarian cancer, and breast cancer patients. (G) Analysis the correlations of plasma Tgfβ1 concentration with MO-/PMN-MDSC ratio across CRC, ovarian cancer, and breast cancer patients. For B, p-values were determined using two sides paired t-test; For C, p values were determined using one-way ANOVA with Tukey test; For A and E–G, Spearman’s rank correlation tests were used, R = Spearman rank correlation coefficient. ***p < 0.001; ****p < 0.0001; ns no significant.
